MicroRNA‑21: A potential therapeutic target in lung cancer (Review)
Authors:
Open Access
- 9 July 2025
- journal article
- review article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 67 (2) , 1-16
Abstract
In this review, the role of microRNA‑21 (miRNA‑21) as an oncogene in lung cancer was investigated. Studies have shown that miRNA‑21 can promote the progression of lung cancer by targeting downstream target genes, and its expression can be modulated by transcription factors, DNA methylation or competitive endogenous RNA as an upstream regulator. This review highlights that miRNA‑21 can promote the progression of lung cancer through multiple signaling pathways, with a focus on the PI3K/AKT, MEK/ERK, TGF‑β/SMAD, Hippo, NF‑κB and STAT3 signaling pathways. Mechanistically, miRNA‑21 plays an important role in the progression of lung cancer by regulating multiple biological processes, such as proliferation, invasion, metastasis, apoptosis and angiogenesis in lung cancer cells. Higher expression of miRNA‑21 is associated with chemotherapy, radiotherapy and immune resistance in lung cancer. Targeting these molecular pathways may be a novel therapeutic strategy for treating lung cancer. Additionally, miRNA‑21 can serve as a biomarker for lung cancer diagnosis, prognosis and treatment response. This review also summarized the following: i) Current methods employed to inhibit the expression of miRNA‑21 in lung cancer, including CRISPR/Cas9 technology; ii) the application of natural anticancer agents, oligonucleotides, small molecules and miRNA sponges; and iii) the nano‑delivery systems developed for miRNA‑21 inhibitors. Finally, the advancements in research on miRNA mimics and inhibitors in clinical trials, which may promote the application of miRNA‑21 in clinical trials in lung cancer, were discussed. Given that lung cancer is a considerable public health challenge, these studies provide new ways of treating patients with lung cancer.Keywords
This publication has 135 references indexed in Scilit:
- Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated with Radioresistance of Lung CancerCancer Investigation, 2015
- Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to CisplatinPLOS ONE, 2015
- In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122Antimicrobial Agents and Chemotherapy, 2015
- Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesisToxicology Letters, 2013
- Miravirsen (SPC3649) can inhibit the biogenesis of miR-122Nucleic Acids Research, 2013
- Moving Beyond the National Lung Screening Trial: Discussing Strategies for Implementation of Lung Cancer Screening ProgramsThe Oncologist, 2013
- Treatment of HCV Infection by Targeting MicroRNANew England Journal of Medicine, 2013
- ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expressionInternational Journal of Oncology, 2012
- miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancerJournal of Cancer Research and Clinical Oncology, 2012
- LNA-mediated microRNA silencing in non-human primatesNature, 2008